* Precision BioSciences Inc DTIL.OQ reported a quarterly
adjusted loss of $4.06 per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-7.80. The mean expectation of
four analysts for the quarter was for a loss of $2.05 per share.
Wall Street expected results to range from $-5.10 to $3.00 per
share.
* Revenue fell 33.6% to $7.04 million from a year ago;
analysts
expected $12.48 million.
* Precision BioSciences Inc's reported EPS for the quarter
was a
loss of $4.06.
* The company reported a quarterly loss of $16.29 million.
* Precision BioSciences Inc shares had risen by 16.4% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Precision
BioSciences Inc is $75.00
This summary was machine generated from LSEG data March 27 at
01:32 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -2.05 -4.06 Missed
Sep. 30 2023 -4.87 -2.10 Beat
Jun. 30 2023 -7.32 -3.00 Beat
Mar. 31 2023 -6.78 -6.90 Missed